Oct 28 (Reuters) - IQVIA Holdings ( IQV ) on Tuesday

narrowed its annual profit forecast, trimming the upper end of

its outlook, as it expects cancellations of research contracts

from pharmaceutical clients to persist into the second half of

this year.

Drugmakers and biotech companies have been cancelling orders

given to contract research firms in response to the President

Trump administration's drug price negotiation program, proposed

federal research budget cuts and tariffs.

IQVIA ( IQV ) now expects annual adjusted profit per share between

$11.85 and $11.95, compared with an earlier forecast of between

$11.75 and $12.05.

The Durham, North Carolina-based company forecast its annual

revenue to be between $16.15 billion and $16.25 billion,

compared with its prior range of $16.1 billion and $16.3

billion.

The company reported quarterly sales at its technology and

analytics unit was $1.63 billion, missing analysts' estimates of

$1.66 billion, according to data compiled by LSEG.

"TAS (unit) delivered solid results despite a tougher

year-over-year comparison, driven by ongoing momentum from drug

launches and the strength of our broader commercial portfolio,"

said CEO Ari Bousbib.

Quarterly sales at its research and development solutions

unit was $2.26 billion, above expectations of $2.23 billion.

IQVIA's ( IQV ) total quarterly revenue rose 5.2% year-on-year to

$4.1 billion, beating analysts' average estimate of $4.08

billion.

On an adjusted basis, it reported a profit of $3 per share

for the quarter ending September 30, above expectations of $2.97

per share.